Corvus Pharmaceuticals Inc [CRVS] stock is trading at $5.78, up 13.33%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CRVS shares have gain 42.01% over the last week, with a monthly amount glided 52.11%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Corvus Pharmaceuticals Inc [NASDAQ: CRVS] stock has seen the most recent analyst activity on August 18, 2023, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $7. On May 27, 2021, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $10 on the stock. Mizuho downgraded its rating to a Neutral and decreased its price target to $4 on February 10, 2021. Mizuho initiated its recommendation with a Buy. ROTH Capital started tracking with a Buy rating for this stock on May 29, 2019, and assigned it a price target of $6. In a note dated August 24, 2017, Credit Suisse upgraded an Neutral rating on this stock.
Corvus Pharmaceuticals Inc [CRVS] stock has fluctuated between $1.05 and $5.22 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Corvus Pharmaceuticals Inc [NASDAQ: CRVS] shares were valued at $5.78 at the most recent close of the market. An investor can expect a potential return of 21.11% based on the average CRVS price forecast.
Analyzing the CRVS fundamentals
Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at -95.12%, Pretax Profit Margin comes in at -91.93%, and Net Profit Margin reading is -91.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.35, Equity is -0.54 and Total Capital is -0.46. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.30 points at the first support level, and at 4.83 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.20, and for the 2nd resistance point, it is at 6.63.
Ratios To Look Out For
For context, Corvus Pharmaceuticals Inc’s Current Ratio is 3.62. In addition, the Quick Ratio stands at 3.62 and the Cash Ratio stands at 1.11.
Transactions by insiders
Recent insider trading involved Jones William Benton,, that happened on May 06 ’24 when 20000.0 shares were purchased. President and CEO, MILLER RICHARD A MD completed a deal on May 06 ’24 to buy 0.58 million shares.
